GP scandalised by £30-an-hour OOH shift
The cardiovascular safety of cox-2 inhibitors remains unproven, warns the US Food and Drug Administration
The agency claimed existing trials were inadequately powered to detect excess cardiovascular events and said it would be reviewing the relevant evidence early next year.
Meanwhile, the first signs of legal action over the withdrawal of rofecoxib (Vioxx) have emerged, with solicitors warning UK cases were currently being compiled and their validity checked.
David Harris, an expert in product and pharmaceutical liability law at solicitors Alexander Harris, said the firm had received more than 50 calls from patients who claimed to have had strokes and serious cardiac events.